REG - Genflow Biosciences - Preliminary Interim Results From Dog Study

Genflow BiosciencesAnnouncement

12/02/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260212:nRSL6468Sa&default-theme=true

RNS Number : 6468S  Genflow Biosciences PLC  12 February 2026

 

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO
CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION
(EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN
UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS
ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS
CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

Genflow Biosciences Plc

 

Positive Preliminary Interim Results from SLAB Clinical Trial of SIRT6 Gene
Therapy in Aged Dogs

 

Genflow Biosciences Plc (LSE: GENF) (OTCQB: GENFF) ("Genflow" or the
"Company"), a European-based biotechnology company focused on the development
of gene therapies for age-related diseases, announces positive preliminary
interim results from its SLAB (Sarcopenia and Longevity in Aged Beagles)
clinical trial evaluating its proprietary SIRT6 centenarian gene therapy in
aged dogs.

 

Trial overview

The randomised, blinded study, conducted by an independent contract research
organisation, enrolled 24 beagle dogs aged over 10 years who were allocated to
four groups: two naked DNA treatment cohorts at different dose levels, a
single-dose AAV8 cohort, and a control group.

 

The interim analysis reflects outcomes observed during the dosing period.
Additional endpoints remain under assessment.

 

Preliminary interim results

All treatment groups demonstrated superior survival compared to the control
group during the dosing period. No adverse events were observed, and all
treatment modalities exhibited a favourable safety and tolerability profile
suitable for use in aged companion animals.

 

Across treatment cohorts, improvements were observed in several functional and
observable endpoints, including quality of life, muscle mass preservation,
frailty index reduction, and coat quality, relative to control animals, which
exhibited expected age-related decline.

 

Ongoing analyses

Several key endpoints remain under evaluation, including biological age
determination using methylation clock analysis and comprehensive muscle biopsy
histology. These analyses are intended to provide further mechanistic and
quantitative validation of the therapy's effects. The Company expects to
provide a comprehensive update on all remaining endpoints within approximately
two months.

 

Commercial and strategic implications

Genflow believes these preliminary results support the potential of its SIRT6
gene therapy as a first-in-class approach to addressing age-related decline in
companion animals and reinforce the programme's relevance to prospective
animal health partners. The Company is actively engaging with animal health
companies regarding potential licensing, co-development, and commercialisation
opportunities.

Dr Eric Leire, Chief Executive Officer of Genflow Biosciences said: ""These
preliminary interim results represent a significant milestone for Genflow and
significantly strengthen our position for animal health partnerships. The
consistency of positive signals across multiple independent endpoints from
survival and quality of life to measures of muscle preservation and frailty
reduction, combined with an excellent safety profile, supports our SIRT6
platform as a credible, differentiated asset for the companion animal market.

 

Based on these encouraging preliminary findings, we are proceeding with the
follow-up phase to assess durability of effects and to monitor for differences
in age-related disease emergence - data that will inform future commercial
discussions. We expect to provide a comprehensive update on all endpoints,
including the critical methylation clock and muscle histology data, within two
months."

 

Contacts

 Genflow Biosciences  Harbor Access
 Dr Eric Leire, CEO   Jonathan Paterson, Investor Relations
 +32-477-495-881      +1 475 477 9401
                      Jonathan.Paterson@Harbor-access.com

 

About Genflow Biosciences

Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a
biotechnology company headquartered in the UK with R&D facilities in
Belgium, is pioneering gene therapies for age-related diseases, with the goal
of promoting longer and healthier lives while mitigating the financial,
emotional, and social impacts of a fast-growing aging global population.
Genflow's lead compound, GF-1002, works through the delivery of a centenarian
variant of the SIRT6 gene which has yielded promising preclinical results.
Genflow's 12-month proof-of-concept clinical trial evaluating their
SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other
programs, include a clinical trial that will explore the potential benefits of
GF-1002 in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis),
the most prevalent chronic liver disease for which there is no effective
treatments. Please visit www.genflowbio.com (http://www.genflowbio.com)   and
follow the Company on LinkedIn
(https://www.linkedin.com/company/genflow-biosciences/?viewAsMember=true) and
X (https://x.com/genflowbio) .

 

DISCLAIMER

The contents of this announcement have been prepared by, and are the sole
responsibility of, the Company.

 

This announcement may contain forward-looking statements. The forward-looking
statements include, but are not limited to, statements regarding the Company's
or the Directors' expectations, hopes, beliefs, intentions or strategies
regarding the future. In addition, any statement that refers to projections,
forecasts or other characterisations of future events or circumstances,
including any underlying assumptions, is a forward-looking statement. The
words "anticipate", "believe", "continue", "could", "estimate", "expect",
"intend", "may", "might", "plan", "possible", "potential", "predict",
"project", "seek", "should", "would" and similar expressions, or in each case
their negatives, may identify forward-looking statements, but the absence of
these words does not mean that a statement is not forward-looking.

 

Forward-looking statements include all matters that are not historical facts.
Forward-looking statements are based on the current expectations and
assumptions regarding the Company, the business, the economy and other future
conditions. Because forward-looking statements relate to the future, by their
nature, they are subject to inherent uncertainties, risks and changes in
circumstances that are difficult to predict. Forward-looking statements are
not guarantees of future performance and the Company's actual financial
condition, actual results of operations and financial performance, and the
development of the industries in which it operates or will operate, may differ
materially from those made in or suggested by the forward-looking statements
contained in this announcement. In addition, even if the Company's financial
condition, results of operations and the development of the industries in
which it operates or will operate, are consistent with the forward-looking
statements contained in this announcement, those results or developments may
not be indicative of financial condition, results of operations or
developments in subsequent periods. Important factors that could cause actual
results to differ materially from those in the forward-looking statements
include regional, national or global, political, economic, social, business,
technological, competitive, market and regulatory conditions.

 

Any forward-looking statement contained in this announcement applies only as
of the date of this announcement and is expressly qualified in its entirety by
these cautionary statements. Factors or events that could cause the Company's
actual plans or results to differ may emerge from time to time, and it is not
possible for the Company to predict all of them. The Company expressly
disclaims any obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained in this announcement to
reflect any change in its expectations or any change in events, conditions or
circumstances on which any forward-looking statement contained in this
announcement is based, unless required to do so by applicable law, the
Prospectus Regulation Rules, the Listing Rules, the Disclosure Guidance and
Transparency Rules of the FCA or the UK Market Abuse Regulation.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCUARVRNUUUAAR



            Copyright 2019 Regulatory News Service, all rights reserved